{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:30:30Z","timestamp":1773081030184,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> The current study identified patients with either essential thrombocythemia (ET) or polycythemia vera (PV) who have survived for at least 20\u2003yr without the development of either acute myeloid leukemia\/myelodysplastic syndrome (AML\/MDS) or myelofibrosis (MF) and compared their presenting features with those in whom these complications occurred in the first 10\u2003yr of disease.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> The study patients were selected from an institutional database of 1061 patients with either ET (<jats:italic>n<\/jats:italic>\u2003=\u2003603) or PV (<jats:italic>n<\/jats:italic>\u2003=\u2003458). In both instances, three distinct groups were delineated and their presenting features compared; group A included patients who have remained AML\/MDS\/MF free after a minimum follow\u2010up of 20\u2003yr; groups B and C included patients who developed either AML\/MDS or MF, respectively, in the first decade of their disease.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The respective number of patients who fulfilled the above\u2010mentioned criteria for inclusion in groups A, B and C were 40, 12 and 8 for ET and 23, 18 and 12 for PV. In ET, compared with both groups B and C, group A displayed significantly fewer patients with less than normal hemoglobin level (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001 and =0.02) or male sex (<jats:italic>P<\/jats:italic>\u2003=\u20030.005 and 0.05), respectively. On multivariable analysis, only anemia sustained its significance. A similar analysis in PV revealed an association between group B and leukocytosis using a leukocyte count threshold of either 10 or 15\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/L (<jats:italic>P<\/jats:italic>\u2003=\u20030.02).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> The current study identifies PV patients with leukocytosis and ET patients with anemia as the most likely to undergo leukemic or fibrotic transformation.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01038.x","type":"journal-article","created":{"date-parts":[[2008,3,7]],"date-time":"2008-03-07T09:00:29Z","timestamp":1204880429000},"page":"386-390","source":"Crossref","is-referenced-by-count":24,"title":["20+\u2003yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis"],"prefix":"10.1111","volume":"80","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra P.","family":"Wolanskyj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca F.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin\u2010Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404750"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404948"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404500"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-942762"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.159"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06009"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.616"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.22.2651"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050555"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00529.x"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404693"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03688.x"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06674.x"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880101)61:1<89::AID-CNCR2820610115>3.0.CO;2-0"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.062"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200250"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401045"},{"key":"e_1_2_4_25_2","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65\u2003years of age. The French Polycythemia Study Group","volume":"89","author":"Najean Y","year":"1997","journal-title":"Blood"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00329494"},{"key":"e_1_2_4_27_2","first-page":"166","volume-title":"Polycythemia Vera and the Myeloproliferative Disorders","author":"Berk PD","year":"1995"},{"key":"e_1_2_4_28_2","first-page":"17","volume-title":"World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues","author":"Vardiman JW","year":"2001"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.04.010"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-042515"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046342"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01038.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01038.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:03:07Z","timestamp":1696964587000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01038.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01038.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01038.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}